Case Studies in the Initial Management of a Person with HIV:
A STEP-HIV Initiative

No Longer Available for Credit
Estimated Time to Complete: 1.0 hours

Jointly Provided by

Support for this activity has been made possible through
an educational grant from Gilead Sciences.

IMPORTANT UPDATE: Dolutegravir (DTG) exposure around the time of conception has been associated with a small but significant increase in the prevalence of infant neural tube defects (NTDs) in Botswana, where food is not routinely fortified with folate. Although this prevalence of NTDs with periconception DTG (0.19%) was higher than the prevalence for NTDs in infants born to women who were receiving efavirenz (0.07%) and women without HIV (0.07%), the risk was not significantly increased compared to women with HIV receiving any non-DTG antiretroviral regimen at conception (0.11%, risk difference [0.09% difference; 95% CI 0.03%, 0.30%]).  Based on this updated evidence, the perinatal guideline panel recommends DTG as preferred for pregnant women, regardless of trimester, and for all women trying to conceive. For more information, click here.

Resource to Support You and Your Care Team: